Anifrolumab in Systemic Lupus Erythematosus. Reply.
作者信息
Morand Eric F, Furie Richard A
机构信息
Monash University, Melbourne, VIC, Australia
Zucker School of Medicine at Hofstra-Northwell, Great Neck, NY.
出版信息
N Engl J Med. 2020 Apr 23;382(17):1666. doi: 10.1056/NEJMc2002191.
PMID:32320577
Abstract
摘要
相似文献
1
Anifrolumab in Systemic Lupus Erythematosus. Reply.阿尼鲁单抗治疗系统性红斑狼疮。回复。
N Engl J Med. 2020 Apr 23;382(17):1666. doi: 10.1056/NEJMc2002191.
2
Anifrolumab in Systemic Lupus Erythematosus.阿尼鲁单抗治疗系统性红斑狼疮
N Engl J Med. 2020 Apr 23;382(17):1665-1666. doi: 10.1056/NEJMc2002191.
3
Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: analysis of the Phase IIb MUSE trial of anifrolumab.狼疮低疾病活动状态（LLDAS）达标可区分系统性红斑狼疮试验中的应答者：阿尼鲁单抗的 IIb 期 MUSE 试验分析。
Ann Rheum Dis. 2018 May;77(5):706-713. doi: 10.1136/annrheumdis-2017-212504. Epub 2018 Feb 2.
4
Comment on: 'Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: post-hoc analysis of the Phase IIb MUSE trial of anifrolumab' by Eric Morand .对埃里克·莫兰德所著《狼疮低疾病活动状态（LLDAS）的达成可区分系统性红斑狼疮试验中的反应者：阿尼鲁单抗IIb期MUSE试验的事后分析》的评论
Ann Rheum Dis. 2019 Nov;78(11):e121. doi: 10.1136/annrheumdis-2018-214468. Epub 2018 Oct 29.
5
Efficacy of anifrolumab in systemic lupus erythematosus: a critical analysis of the TULIP trials.阿尼鲁单抗治疗系统性红斑狼疮的疗效：对TULIP试验的批判性分析
Lupus. 2020 Jul;29(8):1002-1003. doi: 10.1177/0961203320928425. Epub 2020 Jun 3.
6
Response to: 'Comment on: 'Lupus Low Disease Activity State(LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: post-hocanalysis of the Phase IIb MUSE trial of anifrolumab' by Eric Morand et al' by Isenberg.对伊森伯格的回复：“对埃里克·莫兰德等人的‘关于：狼疮低疾病活动状态（LLDAS）的达成在一项系统性红斑狼疮试验中区分了应答者：阿尼鲁单抗IIb期MUSE试验的事后分析’的评论”
Ann Rheum Dis. 2019 Nov;78(11):e122. doi: 10.1136/annrheumdis-2018-214487. Epub 2018 Oct 29.
7
Is there an increased risk of severe COVID-19 among patients with systemic lupus erythematosus treated with anifrolumab?接受阿尼氟单抗治疗的系统性红斑狼疮患者发生重症新型冠状病毒肺炎的风险是否增加？
Lupus. 2023 Mar;32(3):453-455. doi: 10.1177/09612033231153536. Epub 2023 Jan 19.
8
Anifrolumab in systemic lupus erythematosus.阿尼鲁单抗治疗系统性红斑狼疮。
Drugs Today (Barc). 2023 Feb;59(2):53-61. doi: 10.1358/dot.2023.59.2.3521876.
9
Treatment With Anifrolumab for Discoid Lupus Erythematosus.阿尼鲁单抗治疗盘状红斑狼疮
JAMA Dermatol. 2023 Feb 1;159(2):224-226. doi: 10.1001/jamadermatol.2022.5242.
10
Safety and Efficacy of Anifrolumab for Systemic Lupus Erythematosus: Network Meta-analysis.阿尼鲁单抗治疗系统性红斑狼疮的安全性和有效性：网状Meta分析
Am J Ther. 2023;30(5):e487-e490. doi: 10.1097/MJT.0000000000001564. Epub 2022 Aug 29.
引用本文的文献
1
SLE is not a one-size-fits-all disease.SLE 不是一种一刀切的疾病。
J Exp Med. 2023 Jun 5;220(6). doi: 10.1084/jem.20230559. Epub 2023 Apr 25.
Zotero 插件